ECSP077843A - Tratamiento o prevención del prurito - Google Patents

Tratamiento o prevención del prurito

Info

Publication number
ECSP077843A
ECSP077843A EC2007007843A ECSP077843A ECSP077843A EC SP077843 A ECSP077843 A EC SP077843A EC 2007007843 A EC2007007843 A EC 2007007843A EC SP077843 A ECSP077843 A EC SP077843A EC SP077843 A ECSP077843 A EC SP077843A
Authority
EC
Ecuador
Prior art keywords
treatment
prurite
prevention
pruritus
oxaprozin
Prior art date
Application number
EC2007007843A
Other languages
English (en)
Inventor
Morten Sloth Weidner
Original Assignee
Astion Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astion Pharma As filed Critical Astion Pharma As
Publication of ECSP077843A publication Critical patent/ECSP077843A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a métodos y medicamentos para el tratamiento de prurito en general o prurito causado por, o asociado con, enfermedades dermatológicas, incluyendo el tratamiento de la enfermedad de base, mediante la administración tópica en la piel o la administración vía sistémica a un sujeto de oxaprozina o un compuesto estrechamente relacionado o una sal de los mismos.
EC2007007843A 2005-03-30 2007-10-29 Tratamiento o prevención del prurito ECSP077843A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200500437 2005-03-30
DKPA200500438 2005-03-30
US69477405P 2005-06-27 2005-06-27
DKPA200500948 2005-06-27
DKPA200500949 2005-06-27
US69504005P 2005-06-28 2005-06-28

Publications (1)

Publication Number Publication Date
ECSP077843A true ECSP077843A (es) 2008-02-20

Family

ID=36215671

Family Applications (3)

Application Number Title Priority Date Filing Date
EC2007007843A ECSP077843A (es) 2005-03-30 2007-10-29 Tratamiento o prevención del prurito
EC2007007845A ECSP077845A (es) 2005-03-30 2007-10-29 Composiciones y sales dermatológicas para el tratamiento de enfermedades dermatológicas
EC2007007846A ECSP077846A (es) 2005-03-30 2007-10-29 Tratamiento de eczemas

Family Applications After (2)

Application Number Title Priority Date Filing Date
EC2007007845A ECSP077845A (es) 2005-03-30 2007-10-29 Composiciones y sales dermatológicas para el tratamiento de enfermedades dermatológicas
EC2007007846A ECSP077846A (es) 2005-03-30 2007-10-29 Tratamiento de eczemas

Country Status (12)

Country Link
EP (3) EP1707201A1 (es)
JP (3) JP2008534528A (es)
KR (3) KR20080005525A (es)
AU (3) AU2006228869A1 (es)
BR (3) BRPI0609535A2 (es)
CA (3) CA2603300A1 (es)
EA (3) EA200702026A1 (es)
EC (3) ECSP077843A (es)
IL (3) IL186020A0 (es)
MX (3) MX2007012052A (es)
NO (3) NO20075199L (es)
WO (3) WO2006102899A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821537D0 (en) * 2008-11-25 2008-12-31 Union Life Sciences Ltd Therapeutic target
CA2997842A1 (en) * 2015-09-18 2017-03-23 Delivra Inc. Transdermal formulations for delivery of propionic and acetic acid nsaids, and their use in the treatment of nsaid-responsive diseases and conditions
US11406805B2 (en) 2016-08-08 2022-08-09 Avedro, Inc. Systems and methods for cross-linking treatments of an eye
US11229624B2 (en) 2016-10-25 2022-01-25 Ticure Ltd. FABP4 as a therapeutic target in skin diseases
KR20200097297A (ko) * 2017-12-07 2020-08-18 더마반트 사이언시즈 게엠베하 Pde-4 억제제의 국소 연고 제형 및 피부 병태 치료에서의 이의 용도
RU2685436C1 (ru) * 2018-06-22 2019-04-18 ЗАО "ФармФирма "Сотекс" Трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей
JP7514598B2 (ja) * 2018-12-20 2024-07-11 小林製薬株式会社 皮膚外用組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE32084B1 (en) * 1967-06-07 1973-04-04 Wyeth John & Brother Ltd Thiazole derivatives
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles
IE52909B1 (en) * 1981-04-28 1988-04-13 Wyeth John & Brother Ltd Oxazole derivatives
US4659728A (en) * 1985-02-25 1987-04-21 American Home Products Corporation Hydroxy substituted 4,5-diphenyl-2-oxazole propanoic acid
EP0270316A3 (en) * 1986-12-04 1989-12-06 Pfizer Inc. Topical compositions comprising 1-substituted imidazoles and nsaids for treatment of acne
US6090834A (en) * 1993-05-21 2000-07-18 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
PL314036A1 (en) 1993-10-20 1996-08-05 Boots Co Plc Pharmaceutical composition
JPH07316075A (ja) 1994-05-26 1995-12-05 Pola Chem Ind Inc 皮膚外用剤
GB9606429D0 (en) 1996-03-27 1996-06-05 Boots Co Plc Pharmaceutical compositions
AU718030B2 (en) * 1996-05-20 2000-04-06 G.D. Searle & Co. Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
US5976566A (en) * 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
WO2005009342A2 (en) 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050232957A1 (en) 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin

Also Published As

Publication number Publication date
EA200702023A1 (ru) 2008-04-28
MX2007012052A (es) 2008-02-22
ECSP077846A (es) 2008-02-20
EA200702027A1 (ru) 2008-02-28
JP2008534526A (ja) 2008-08-28
EA200702026A1 (ru) 2008-04-28
CA2603297A1 (en) 2006-10-05
AU2006228869A1 (en) 2006-10-05
NO20075227L (no) 2007-12-09
WO2006102899A2 (en) 2006-10-05
BRPI0607648A2 (pt) 2009-09-22
WO2006102898A2 (en) 2006-10-05
WO2006102899A3 (en) 2006-12-28
KR20080005525A (ko) 2008-01-14
WO2006102900A1 (en) 2006-10-05
BRPI0609535A2 (pt) 2010-04-13
IL186021A0 (en) 2008-02-09
EP1707201A1 (en) 2006-10-04
KR20080005526A (ko) 2008-01-14
AU2006228871A1 (en) 2006-10-05
ECSP077845A (es) 2008-02-20
IL186020A0 (en) 2008-01-20
NO20075218L (no) 2007-12-27
KR20080011280A (ko) 2008-02-01
MX2007012050A (es) 2008-03-11
MX2007012051A (es) 2008-02-22
EP1707200A1 (en) 2006-10-04
CA2605121A1 (en) 2006-10-05
JP2008534527A (ja) 2008-08-28
WO2006102898A3 (en) 2006-12-28
EP1707199A1 (en) 2006-10-04
BRPI0609653A2 (pt) 2010-04-20
JP2008534528A (ja) 2008-08-28
AU2006228870A1 (en) 2006-10-05
NO20075199L (no) 2008-01-02
IL186022A0 (en) 2008-02-09
CA2603300A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
ES2526648T3 (es) Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno
MXPA05011208A (es) Uso de ivermectina para el tratamiento de desordenes dermatologicos.
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
AR062402A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento del cancer de piel
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
EA200802208A1 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AR096402A1 (es) Medicamento de metformina y dihidroquercetina
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
DK1680128T3 (da) Myo-inositolhexaphosphat til topisk anvendelse
MX2009011900A (es) Curacion de herida diabetica.
AR054249A1 (es) Tratamiento de enfermedades del tejido conectivo de la piel
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
AR076505A1 (es) Uso de alopurinol para el tratamiento de la reaccion cutanea en manos -pies
RU2008127882A (ru) Лечение пищевода барретта
NO20075199L (no) Treatment or prevention of pruritus